AroCell AB: Abstract published presenting AroCell TK 210 ELISA from the PROMIX study at the European Society for Medical Onco...
November 08 2017 - 3:30AM
AroCell AB (publ) announces today
that the abstract entitled: "Quantification of cell loss in breast
cancer during neoadjuvant treatment (NACT) assessed by serum
thymidine kinase protein concentrations (sTK1)", by B Tribukait et
al was published today by the ESMO Asia congress organizers
(https://cslide.ctimeetingtech.com/asia2017/attendee/confcal/session/calendar?q=Tribukait).
The
investigators quantified cell loss using the AroCell TK 210 ELISA
kit to measure serum TK1 in serial samples from 145 breast cancer
patients undergoing chemotherapy before surgery. Serum TK1 levels
correlated to clinical/radiologically determined tumor response
after cycles 2, 4 and 6, as well as pathologically determined
response and disease-free survival. (To read the full abstract,
please visit the ESMO Asia 2017 website.)
The investigators found that serum TK1 levels measured at the
base-line and after completion of four cycles of treatment
correlated significantly with clinical/radiological response during
treatment and tumor-status at surgery. "This study shows that the
reduction of tumor size and response to therapy can be assessed
with our TK 210 ELISA" says Jan Stålemark, AroCell CEO. "Our
product TK 210 ELISA was used in this study to investigate whether
or not TK1 concentration can be a significant predictor of
treatment response during chemotherapy of breast cancer. This is
another study showing that serum TK1 measured with TK 210 ELISA is
a promising biomarker for monitoring treatment response and
possibly as a tool in clinical drug development. It gives a prompt
signal on whether the new therapy works or not".
For additional
information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706926206
info@arocell.com
www.arocell.com
This information is information
that AroCell is obliged to make public pursuant to the EU Market
Abuse Regulation and the Securities Markets Act. The information
was submitted for publication, through Jan Stålemark, at 09:30 CET on 08 November 2017.
About AroCell
AroCell AB (publ) is a Swedish
company that develops standardized modern blood tests to support
the prognosis and follow up of cancer patients. AroCell's new
technology is based on patented methods to measure Thymidine Kinase
1 (TK1) protein levels in a blood sample. The TK 210 ELISA test
provides valuable information mainly about the condition of cancer
patients. This may help clinicians to optimize treatment strategies
and estimate the risk of recurrence of the tumor disease during the
monitoring of the disease. AroCell (AROC) is listed at Nasdaq First
North and has about 2,500 shareholders. For more information,
please see www.arocell.com. Redeye AB is
AroCell's Certified Adviser.
AroCell press release Final Nov 8
2017
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: AroCell AB via Globenewswire
Archrock (NYSE:AROC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Archrock (NYSE:AROC)
Historical Stock Chart
From Apr 2023 to Apr 2024